Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM-Reference-Cited by-同舟云学术

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM

Published:2012-10 Issue:10 Volume:23 Page:2566-2572
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hadji P.,Kieback D.G.,Tams J.,Hasenburg A.,Ziller M.

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/10/2566/13786238/mds055.pdf

Reference28 articles.

1. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol,2009

2. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer;Chlebowski;Breast,2009

3. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial;Coombes;Lancet,2007

4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial;Forbes;Lancet Oncol,2008

5. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer;Mouridsen;N Engl J Med,2009

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and future advances in practice: aromatase inhibitor–induced arthralgia;Rheumatology Advances in Practice;2024-01-01

2. The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy;Frontiers in Oncology;2023-07-07

3. Primary care and preventable hospitalizations among Medicare beneficiaries with non-metastatic breast cancer;Journal of Cancer Survivorship;2022-01-22

4. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management;Frontiers in Endocrinology;2021-07-27

5. Management of Aromatase Inhibitor–Induced Musculoskeletal Symptoms;JCO Oncology Practice;2020-11